Dai ichi Life Insurance Company Ltd Has $11.73 Million Stake in Amgen Inc. $AMGN

Dai ichi Life Insurance Company Ltd lowered its position in Amgen Inc. (NASDAQ:AMGN) by 5.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,348 shares of the medical research company’s stock after selling 2,060 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Amgen were worth $11,733,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp raised its holdings in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after buying an additional 1,287,310 shares during the last quarter. Capital World Investors grew its holdings in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. Geode Capital Management LLC increased its position in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Finally, Norges Bank acquired a new stake in Amgen in the 4th quarter valued at about $2,164,162,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on AMGN shares. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Mizuho boosted their price objective on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 16th. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Canaccord Genuity Group began coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective on the stock. Finally, Truist Financial lifted their target price on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research note on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $356.62.

Amgen Trading Up 1.2%

AMGN opened at $376.04 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market cap of $202.95 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.76 and a beta of 0.41. The firm has a 50 day simple moving average of $351.28 and a 200 day simple moving average of $351.80. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the business posted $4.90 earnings per share. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.